Managing toxicities and optimal dosing of targeted drugs in advanced kidney cancer

被引：0
|
作者：
Seruga, B. [1 ]
Gan, H. K. [1 ]
Knox, J. J. [1 ]
机构：
[1] Univ Toronto, Princess Margaret Hosp, Dept Med Oncol & Hematol, Div Hematol & Med Oncol, Toronto, ON, Canada
来源：
CURRENT ONCOLOGY | 2009年 / 16卷
关键词：
Sunitinib; sorafenib; temsirolimus; toxicity; side effects; management; RENAL-CELL CARCINOMA; TYROSINE KINASE INHIBITOR; CARDIAC-HYPERTROPHY; INTERFERON-ALPHA; DOUBLE-BLIND; SUNITINIB; HYPOTHYROIDISM; HYPERTENSION; MANAGEMENT; SAFETY;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The toxicities of new, targeted drugs may diminish their effectiveness in advanced kidney cancer if those toxicities are not recognized and properly addressed early in patient treatment. Most of the drug-related toxicities in advanced kidney cancer are manageable with supportive care, obviating a need for long interruptions, dose reductions, or permanent discontinuation of the treatment.
引用
收藏
页码：S54 / S61
页数：8
相关论文
共 50 条
  • [11] Adherence, Dosing, and Managing Toxicities With Trifluridine/Tipiracil (TAS-102)
    Lee, James J.
    Chu, Edward
    CLINICAL COLORECTAL CANCER, 2017, 16 (02) : 85 - 92
  • [12] Navigating an Optimal Treatment Course for Advanced Kidney Cancer
    Teply, Benjamin A.
    ONCOLOGY-NEW YORK, 2021, 35 (06): : 308 - 309
  • [13] Managing The Skin Toxicities From New Melanoma Drugs
    Mavropoulos, John C.
    Wang, Timothy S.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2014, 15 (02) : 281 - 301
  • [14] Managing The Skin Toxicities From New Melanoma Drugs
    John C. Mavropoulos
    Timothy S. Wang
    Current Treatment Options in Oncology, 2014, 15 : 281 - 301
  • [15] Risk Assessment of Drug Interaction Potential and Concomitant Dosing Pattern on Targeted Toxicities in Pediatric Cancer Patients
    Jeffrey S. Barrett
    Dimple Patel
    Erin Dombrowsky
    Gaurav Bajaj
    Jeffrey M. Skolnik
    The AAPS Journal, 2013, 15 : 775 - 786
  • [16] Risk Assessment of Drug Interaction Potential and Concomitant Dosing Pattern on Targeted Toxicities in Pediatric Cancer Patients
    Barrett, Jeffrey S.
    Patel, Dimple
    Dombrowsky, Erin
    Bajaj, Gaurav
    Skolnik, Jeffrey M.
    AAPS JOURNAL, 2013, 15 (03): : 775 - 786
  • [17] RATING THE TOXICITIES OF CANCER DRUGS
    STAM, HJ
    CHALLIS, GB
    AMERICAN JOURNAL OF NURSING, 1988, 88 (10) : 1362 - 1363
  • [18] Recognizing and managing on toxicities in cancer immunotherapy
    Yang, Liu
    Yu, Huifang
    Dong, Shuang
    Zhong, Yi
    Hu, Sheng
    TUMOR BIOLOGY, 2017, 39 (03)
  • [19] Management of immune-mediated toxicities and their implications in the outcomes of advanced kidney cancer
    Roy, Arya Mariam
    George, Saby
    IMMUNOTHERAPY, 2023, 15 (06) : 397 - 400
  • [20] Three molecularly targeted drugs tested in kidney cancer clinical trials
    Tuma, RS
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (17) : 1270 - 1271
12345